Blood Pressure-Lowering Efficacy of Amiloride versus Enalapril as Add-On Drugs in Patients with Uncontrolled Blood Pressure Receiving Hydrochlorothiazide

References

• Fuchs FD, Guerrero P, Gus M. What is next when the first blood pressure-lowering drug is not sufficient?. Expert Rev Cardiovasc Ther. 2007; 5: 435–439
   PubMedGoogle Scholar
• PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041
   PubMed Web of Science ®Google Scholar
• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967; 202: 1028–1034
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-Dell, et al. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease—the International Verapamil-Trandolapril Study (INVEST): A randomised controlled trial. JAMA. 2003; 290: 2805–2816
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipina adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet 2005; 366: 895–906
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004; 292: 2849–2859
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007; 25: 1105–1187
   PubMed Web of Science ®Google Scholar
• Stertiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens. 2005; 23: 883–889
   PubMed Web of Science ®Google Scholar
• Agrawal R, Marx A, Haller H. Efficacy and safety of lercarnidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens. 2006; 24: 185–192
   PubMed Web of Science ®Google Scholar
• Sierra A, Gil-Extremera B, Calvo C, et al. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs. losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens. 2004; 18: 215–222
   PubMed Web of Science ®Google Scholar
• Backhouse CI, Platt J, Crawford RJ, Allman S. An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension. Curr Med Res Opin. 1988; 10: 690–698
   PubMed Web of Science ®Google Scholar
• Rappelli A, Ambrosio GB, Caiazza A, et al. Evaluation of the safety and efficacy of the lisinopril + hydrochlorothiazide and captopril + hydrochlorothiazide combinations in the treatment of essential arterial hypertension. Minerva Med. 1992; 83: 57–64
   PubMedGoogle Scholar
• Luccioni R, Sever OS, Perri TD, et al. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens. 1995; 13: 1847–1851
   PubMed Web of Science ®Google Scholar
• Clement J, Schwebig A, Mazaud C, Justal A, Bricaud H. Comparative study of the efficacy and tolerance of capozide and moduretic administered in a single daily dose for the treatment of chronic moderate arterial hypertension. Postgrad Med J. 1986; 62(Suppl. 1)S132–S134
   PubMedGoogle Scholar
• Mammarella A, Paoletti V, Barlattani M, Leone G, Filippello CP, Mariani AR. Efficacy and tolerability of captopril-hydrochlorothiazide vs amiloride-hydrochlorothiazide combination in mild to moderate arterial hypertension. Clin Ter 1989; 129: 129–134
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA. 2003; 289: 2560–2572
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000; 35: 1025–1030
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006; 48: 1–6
   PubMed Web of Science ®Google Scholar
• MRC Working Party. Medical research council trial of treatment of hypertension in older adults: Principal results. BMJ 1992; 304: 405–412
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366–372
   PubMed Web of Science ®Google Scholar
• Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, MacGregor GA. Amiloride, a specific drug for hypertension in black people with T594M variant?. Hypertension 2002; 40: 13–17
   PubMed Web of Science ®Google Scholar
• Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: An effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens 2005; 19: 451–455
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Gus M, Moreira LB, Moreira WD, Gonçalves SC, Nunes G. Headache is not more frequent among patients with moderate to severe hypertension. J Hum Hypertens 2003; 17: 787–790
   PubMed Web of Science ®Google Scholar
• Gus M, Fuchs FD, Pimentel M, Rosa D, Melo AG, Moreira LB. Behavior of ambulatory blood pressure surrounding episodes of headache in mildly hypertensive patients. Arch Intern Med. 2001; 161: 252–255
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chem. 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Granger B, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJV, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomized, controlled clinical trial. Lancet 2005; 366: 2005–2011
   PubMed Web of Science ®Google Scholar
• The National Heart, Lung, and Blood Institute Wording Group on Future Directions in Hypertension Treatment Trials. Major clinical trials of hypertension: What should be done next?. Hypertension 2005; 46: 1–6
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: An update including the 2003–2004 secondary prevention trials. Hypertens Res. 2005; 28: 385–407
   PubMed Web of Science ®Google Scholar
• Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367: 463–467
   PubMed Web of Science ®Google Scholar
• Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilldahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004; 22: 2217–2226
   PubMed Web of Science ®Google Scholar
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002; 288: 2981–2997
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Mehler PS. Angiotensin-converting enzyme inhibitors and diuretics: Optimal combination therapy. Ann Intern Med. 2004; 141: 893
   PubMed Web of Science ®Google Scholar
• IV Brazilian Guidelines in Arterial Hypertension Work Groups. IV Brazilian guidelines in arterial hypertension. Arq Bras Cardiol 2004; 82(Suppl. 4)7–22
   PubMedGoogle Scholar
• Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lins X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994; 330: 1852–1857
   PubMed Web of Science ®Google Scholar
• Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624–1632
   PubMed Web of Science ®Google Scholar